Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UCB, Dermira to develop and commercialize Cimzia in dermatology
The deal aims to broaden patient access to Cimzia and make it available to patients with psoriasis, a chronic autoimmune disorder. Currently, Cimzia is not approved for the
The deal aims to broaden patient access to Cimzia and make it available to patients with psoriasis, a chronic autoimmune disorder. Currently, Cimzia is not approved for the
In April 2013, GSK hired Humphrey’s Chinese corporate investigations business, ChinaWhys, to investigate who is behind a suspected smear campaign against the company. In July 2013, Humphrey and
The approval follows a priority review of the Beleodaq new drug application (NDA) and was an Early Approval action prior to the 09 August 2014 PDUFA (Prescription Drug
As part of the agreement, Seragon will receive an upfront cash payment of $725m from Genentech and additional contingent payments of up to $1bn based on achievement of
The company said that the currently marketed bendamustine HCI product is a lyophilized powder that requires reconstitution and dilution in 500mL of saline or a sodium chloride /
The new patent, US Patent No. 8,765,913, includes claims covering certain FZD-Fc compositions of matter and also claims covering methods of treating cancer with such soluble receptors. The
The company is focused on developing targeted and programmable therapeutics called Accurins. Both the firms have notified each other that they will not be exercising their options to
Currently, andexanet alfa is in Phase III ANNEXA (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of fXA Inhibitors) studies. The antidote is designed to reverse the
The MAAs are based on data from the large Phase III TOviTO clinical trial program and further regulatory filings in other countries will be announced in due course.
The company has submitted national marketing authorization variations for Somatuline Autogel 120mg injection to the drug regulatory authorities in 25 countries of the EU. Upon submissions in EU